LETero Tablet contains Letrozole 2.5 mg, a non-steroidal aromatase inhibitor indicated primarily for the treatment of hormone receptor-positive breast cancer in postmenopausal women. Letrozole works by inhibiting the aromatase enzyme, which is responsible for the peripheral conversion of androgens to estrogens, thereby reducing circulating estrogen levels and limiting the growth of estrogen-dependent tumors. LETero is commonly prescribed as adjuvant therapy following surgery or radiotherapy, as well as for advanced or metastatic breast cancer. The recommended dosage is typically one 2.5 mg tablet taken orally once daily, with or without food, as directed by a healthcare professional. Patients should be monitored for potential side effects, including hot flashes, arthralgia, fatigue, and bone density reduction, necessitating periodic bone health assessments. LETero is contraindicated in premenopausal women, during pregnancy, and in patients with hypersensitivity to letrozole or any excipients. Caution is advised when co-administered with drugs affecting hepatic enzymes or those that may exacerbate osteoporosis. Regular clinical evaluation and laboratory monitoring are essential to ensure therapeutic efficacy and manage adverse reactions. LETero Tablet should be stored at room temperature, protected from moisture and light. Use LETero strictly under medical supervision to optimize treatment outcomes in breast cancer management.